跳至主要内容
临床试验/NCT05068011
NCT05068011招募中不适用

Differential Target Multiplexed Spinal Cord Stimulation: a Multicenter Cohort Study

Moens Maarten14 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2021年10月6日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
Moens Maarten
入组人数
250
试验地点
14
主要终点
Overall pain intensity with Visual Analogue Scale (VAS)

研究概览

简要总结

Evaluation of the effectiveness of differential target multiplexed spinal cord stimulation for treatment of chronic back and leg pain. Additionally, a subgroup analysis will be performed to evaluate potential differences between paddle/surgical leads versus percutaneous leads.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with severe chronic pain (> 5 on numeric rating scale, NRS) for at least 6 months due to FBSS (PSPS T2) and suitable for treatment with DTM SCS according to the treating physician
  • Age > 18 years
  • Patient has been informed of the study procedures and has given written informed consent
  • Patient willing to comply with study protocol including attending the study visits

排除标准

  • Expected inability of the patient to receive or properly operate the spinal cord stimulation system
  • History of coagulation disorder, lupus erythematosus, diabetic neuropathy, rheumatoid arthritis, or morbus Bechterew
  • Active malignancy
  • Addiction to drugs, alcohol (>5 units per day) and/or medication
  • Evidence of an active disruptive psychiatric disorder or other known condition that may impact perception of pain, compliance to the intervention, and/or ability to evaluate treatment outcome as determined by investigator
  • Immune deficiency (e.g. HIV positive, immunosuppressive treatment)
  • Life expectancy < 1 year
  • Local infection or any other skin disorder at site of incision
  • Pregnancy
  • Other implanted active medical device

结局指标

主要结局

Overall pain intensity with Visual Analogue Scale (VAS)

时间窗: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months

Overall pain, defined as a combination of back and leg pain, but not pain from other body parts, measured with the VAS (100mm)

次要结局

  • Clinical holistic responder status(The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months)
  • Pain catastrophizing(The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months)
  • Symptoms of central sensitisation.(The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months)
  • (Serious) adverse events(Throughout study period)
  • Proportion of successful DTM trials.(Evaluated after final SCS implantation)
  • Patient expectations concerning SCS(Evaluated at baseline visit)
  • Pain medication use(The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months)
  • Patient global impression of change(Evaluated at 1 month, 6 months and 12 months of DTM SCS.)
  • Back pain intensity with Visual Analogue Scale (VAS)(The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months)
  • Health related quality of life(The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months)
  • Patients' individual competencies for self-management(The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months)
  • DTM SCS stimulation parameters(Registration at 1 month, 6 months and 12 months of DTM SCS)
  • Leg pain intensity with Visual Analogue Scale (VAS)(The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months)
  • Functional disability(The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months)
  • Work status(The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months)
  • Anxiety and Depression.(The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months)
  • Time spent in body postures(The data will be extracted from SCS implantation up to 1 month of SCS, from 1 month of SCS up to 6 months and from 6 months up to 12 months)
  • Battery consumption(Registration at 1 month, 6 months and 12 months of DTM SCS)
  • Healthcare utilisation.(The change between implantation and evaluation at 1 month, 6 months and 12 months of DTM SCS)
  • Prevalence of technical issues with regard to DTM SCS programming(Throughout study period)

研究者

发起方
Moens Maarten
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Moens Maarten

principal investigator

Universitair Ziekenhuis Brussel

研究点 (14)

Loading locations...

相似试验